Hotomi Muneki, Ikeda Yorihiko, Suzumoto Masaki, Yamauchi Kazuma, Green Bruce A, Zlotnick Gary, Billal Dewan S, Shimada Jun, Fujihara Keiji, Yamanaka Noboru
Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, Kimiidera 811-1, Wakayama-shi 641-0032, Japan.
Vaccine. 2005 Jan 26;23(10):1294-300. doi: 10.1016/j.vaccine.2004.08.042.
Outer membrane protein P4, together with P6, is highly conserved among all typeable and nontypeable strains of Haemophilus influenzae (H. influenzae). Thus, the protein is an attractive antigen for the inclusion in a vaccine against nontypeable H. influenzae (NTHi). However, the ability of P4 to induce antibodies protective against NTHi infections is still controversial. In this study, we investigated the specific mucosal immune responses against NTHi induced by intranasal immunization with the lipidated form of recombinant P4 protein (rP4) and non-fatty acylated recombinant P6 protein (rP6) with or without cholera toxin (CT) in BALB/c mice model. Intranasal immunization with either rP4+CT, a mixture of rP4 and rP6+CT, or rP4 and rP6 without CT elicited anti-rP4 specific IgG antibody in serum of mice. Intranasal immunization with either rP4+CT or a mixture of rP4, rP6+CT elicited anti-rP4 specific IgA antibody in nasopharyngeal washing (NPW), while intranasal immunization with rP4 and rP6 without CT did not induced anti-rP4 specific IgA antibody responses in NPWs. Sera from mice intranasally immunized with rP4+CT and a mixture of rP4, rP6+CT also showed bactericidal activity. Significant clearance of NTHi in nasopharynx was seen 3 days after the inoculation of live NTHi in mice intranasally immunized with rP4+CT. The current findings suggested that P4 would be a useful antigen as the component of the vaccine to induce protective immune responses against NTHi. The use of an intranasal vaccine composed of the different surface protein antigens is an attractive strategy for the development of a vaccine against NTHi.
外膜蛋白P4与P6一起,在所有可分型和不可分型的流感嗜血杆菌菌株中高度保守。因此,该蛋白是一种有吸引力的抗原,可用于包含在抗不可分型流感嗜血杆菌(NTHi)疫苗中。然而,P4诱导针对NTHi感染的保护性抗体的能力仍存在争议。在本研究中,我们在BALB/c小鼠模型中,研究了用重组P4蛋白(rP4)的脂化形式和非脂肪酰化重组P6蛋白(rP6),联合或不联合霍乱毒素(CT)进行鼻内免疫诱导的针对NTHi的特异性黏膜免疫反应。用rP4+CT、rP4和rP6+CT的混合物或不含CT的rP4和rP6进行鼻内免疫,均可在小鼠血清中诱导出抗rP4特异性IgG抗体。用rP4+CT或rP4、rP6+CT的混合物进行鼻内免疫,可在鼻咽冲洗液(NPW)中诱导出抗rP4特异性IgA抗体,而用不含CT的rP4和rP6进行鼻内免疫,在NPW中未诱导出抗rP4特异性IgA抗体反应。用rP4+CT和rP4、rP6+CT的混合物进行鼻内免疫的小鼠血清也显示出杀菌活性。在用rP4+CT进行鼻内免疫的小鼠接种活NTHi后3天,可见鼻咽部NTHi的显著清除。目前的研究结果表明,P4作为疫苗成分诱导针对NTHi的保护性免疫反应将是一种有用的抗原。使用由不同表面蛋白抗原组成的鼻内疫苗是开发抗NTHi疫苗的一种有吸引力的策略。